Long lasting octreotide LAR therapy in non functioning pancreatic neuroendocrine carcinoma
Non functioning endocrine pancreatic tumors (NF-PETs) have absent or low hormone secretion without symptoms and constitue ~60% of PETs. At diagnosis more than 50% of patients have liver metastases and almost 40% are not candidates for radical surgery because of either locally advanced disease or unr...
Main Authors: | Ivan Lolli, Antonio Logroscino, Simona Vallarelli, Maria A. Monteduro, Antonella Gentile, Giuseppe Troccoli |
---|---|
Format: | Article |
Language: | English |
Published: |
SEEd
2015-10-01
|
Series: | Clinical Management Issues |
Subjects: | |
Online Access: | https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1067 |
Similar Items
-
Role of high dose octreotide LAR for the treatment of GEP-NETs
by: Giulia M. Franchi, et al.
Published: (2009-03-01) -
Octreotide in the treatment of neuroendocrine carcinomas: Is the success achieved?
by: L. Yu. Morgunov
Published: (2015-06-01) -
Neuroendocrine Tumours: a Literature Review
by: K. V. Menshikov, et al.
Published: (2021-05-01) -
The Clinico-epidemiologic Characteristics of Iraqi Patients with Neuroendocrine Tumors and Their Response to Long Acting Octreotide
by: Marwah K. Abdulfattah, et al.
Published: (2016-01-01) -
Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice
by: Kiesewetter, B., et al.
Published: (2022)